Abstract
Genetic redirection of lymphocytes that have been engineered to recognize antigens other than those originally programmed by their rearranged germlines is a potentially powerful immunotherapeutic tool. The rationale for the protocol described here is that many cancers and persistent or latent viruses have developed strikingly similar mechanisms of evading attack by host immunity that can often be overcome by redirection of host lymphocytes using chimeric T-cell receptor (chTCR) genes. However, for human peripheral blood lymphocytes (PBLs), this is generally regarded as a technically demanding procedure with unacceptably low efficiency using either contemporary transfection methods or retroviral transduction. One of the main difficulties with retroviruses is their reliance on rapidly dividing cells for integration of their genomes carrying the desired chTCR. Here we describe a highly efficient protocol that uses a lentivirus/vesicular stomatitis virus pseudotyped virus to engineer CD3/CD28-stimulated human peripheral blood cells (i.e., primarily T cells), with near 100% efficiency.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Eshhar, Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol. Immunother. 45, 131–136 (1997).
Gross, G., Gorochov, G., Waks, T. & Eshhar, Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant. Proc. 21, 127–130 (1989).
Pinthus, J.H. et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 63, 2470–2476 (2003).
Pinthus, J.H. et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest. 114, 1774–1781 (2004).
Schule, S. et al. Selective gene transfer to T lymphocytes using coreceptor-specific [MLV(HIV)] pseudotype vectors in a transgenic mouse model. Virology 351, 237–247 (2006).
Hombach, A. et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J. Immunol. 167, 6123–6131 (2001).
Hombach, A. et al. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int. J. Cancer 88, 115–120 (2000).
Hombach, A. et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther. 6, 300–304 (1999).
Haynes, N.M. et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J. Immunol. 166, 182–187 (2001).
Haynes, N.M. et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100, 3155–3163 (2002).
Doherty, P.C., Tripp, R.A. & Sixbey, J.W. Evasion of host immune responses by tumours and viruses. Ciba Found. Symp. 187, 245–256 (1994).
Simmons, A. & Tscharke, D.C. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J. Exp. Med. 175, 1337–1344 (1992).
Liu, T., Khanna, K.M., Carriere, B.N. & Hendricks, R.L. Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J. Virol. 75, 11178–11184 (2001).
Liu, T., Khanna, K.M., Chen, X., Fink, D.J. & Hendricks, R.L. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J. Exp. Med. 191, 1459–1466 (2000).
Ory, D.S., Neugeboren, B.A. & Mulligan, R.C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93, 11400–11406 (1996).
Yang, Y. et al. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum. Gene Ther. 6, 1203–1213 (1995).
Arai, T. et al. A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines. J. Virol. 72, 1115–1121 (1998).
Kahl, C.A., Pollok, K., Haneline, L.S. & Cornetta, K. Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: variable transduction related to cell type and culture conditions. Mol. Ther. 11, 470–482 (2005).
Logan, A.C. et al. Factors influencing the titer and infectivity of lentiviral vectors. Hum. Gene Ther. 15, 976–988 (2004).
Kafri, T. Gene delivery by lentivirus vectors an overview. Methods Mol. Biol. 246, 367–390 (2004).
Verdier, F. & Descotes, J. Preclinical safety evaluation of human gene therapy products. Toxicol. Sci. 47, 9–15 (1999).
Russell, D.W., Berger, M.S. & Miller, A.D. The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum. Gene Ther. 6, 635–641 (1995).
Rigg, R.J. et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology 218, 290–295 (1996).
Croyle, M.A. et al. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78, 912–921 (2004).
Chen, J., Dave, S.K. & Simmons, A. Prevention of genital herpes in a guinea pig model using a glycoprotein D-specific single chain antibody as a microbicide. Virol. J. 1, 11 (2004).
Simmons, A., Robert, W.P., Kolokoltsov, A.A. & Davey, R.A. Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro. Virol. J. 3, 8 (2006).
Schagen, F.H., Rademaker, H.J., Fallaux, F.J. & Hoeben, R.C. Insertion vectors for gene therapy. Gene Ther. 7, 271–272 (2000).
Bartz, S.R. & Vodicka, M.A. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods 12, 337–342 (1997).
Hardy, D.A. & Ling, N.R. Effects of some cellular antigens on lymphocytes and the nature of the mixed lymphocyte reaction. Nature 221, 545–548 (1969).
Schwarz, M.R., Tyler, R.W. & Everett, N.B. Mixed lymphocyte reaction: an in vitro test for antilymphocytic serum activity. Science 160, 1014–1017 (1968).
Steinman, R.M. & Inaba, K. Stimulation of the primary mixed leukocyte reaction. Crit. Rev. Immunol. 5, 331–348 (1985).
Acknowledgements
The authors wish to thank Robert Davey and Andrey Kolokoltsov of UTMB for invaluable advice and assistance with this procedure and the Gillson Longenbaugh Foundation of Houston for funding the project.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Simmons, A., Jantz, K. Use of a lentivirus/VSV pseudotype virus for highly efficient genetic redirection of human peripheral blood lymphocytes. Nat Protoc 1, 2688–2700 (2006). https://doi.org/10.1038/nprot.2006.409
Published:
Issue Date:
DOI: https://doi.org/10.1038/nprot.2006.409
This article is cited by
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.